Golimumab News and Research

RSS
New research reveals effective treatments for gastrointestinal conditions

New research reveals effective treatments for gastrointestinal conditions

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New guidelines offer guidance on how and when to switch between RA drug classes

New guidelines offer guidance on how and when to switch between RA drug classes

NHS approves new rheumatoid arthritis drug RoActemra

NHS approves new rheumatoid arthritis drug RoActemra

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Merck third quarter global sales increase 8% to $12.0 billion

Merck third quarter global sales increase 8% to $12.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson provides further details regarding distribution rights for REMICADE, SIMPONI

Johnson & Johnson provides further details regarding distribution rights for REMICADE, SIMPONI

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

Merck reports GAAP net income of $861 million for 2010

Merck reports GAAP net income of $861 million for 2010

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

SIMPONI injection improves inflammation, structural damage in RA patients

SIMPONI injection improves inflammation, structural damage in RA patients

Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta